Two developments signal parallel moves to industrialize and better control cell therapies. Cellares executives discussed using automation, closed manufacturing systems and global networks to transform autologous and allogeneic cell therapies from boutique products into scalable medicines. The approach emphasizes process standardization, reduced manual handling, and regional manufacturing hubs. Complementing manufacturing advances, researchers engineered a drug‑gated light‑activation system to program CAR‑antigen pairing and temporally control CAR T cell activity. The chemo‑optogenetic method enables on‑demand opening and closing of intercellular signaling to limit off‑target toxicity; in technical terms, it couples a small‑molecule gate with light to achieve high spatiotemporal precision. Together these technological and control advances target two core barriers—manufacturing capacity and safety regulation—potentially accelerating wider clinical deployment of cell therapies.